<DOC>
	<DOCNO>NCT01256021</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Meditoxin® treatment child cerebral palsy .</brief_summary>
	<brief_title>The Efficacy Safety MEDITOXIN® Children With Cerebral Palsy</brief_title>
	<detailed_description>The allocated subject inject Meditoxin® 4U/kg body weight ( patient hemiplegia ) 6U/kg body weight ( patient diplegia ) affect gastrocnemius muscle treatment patient suffer Equinus Foot Deformity pediatric cerebral palsy due spasticity . The efficacy safety evaluate 12weeks 3 follow visit .</detailed_description>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Pediatric patient age 2 18 year diagnosis spastic cerebral palsy Patients toewalking due peroneal muscle spasticity ( patient equinus foot deformity due spasticity ) Patients voluntarily consent participate study whose legally acceptable representative sign informed consent form ( patient able write , his/her signature also obtain ) . Patients previously receive botulinum toxin within 3 month prior study entry Patients know hypersensitivity botulinum toxin Patients require leg , foot ankle surgery present Patients severe athetoid movement Patients participate investigational study present Patients , investigator 's discretion , suitable study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>